Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancer

Small cell carcinoma of the bladder (SCCB) is a rare and aggressive variant of bladder cancer requiring multimodal treatment. We present a case of an 82-year-old male with SCCB with bulky pelvic adenopathy treated with a novel neoadjuvant combination of carboplatin, etoposide, and durvalumab with co...

Full description

Saved in:
Bibliographic Details
Main Authors: Victoria Gonzalez, Edward Linton, Timothy Boyce, Laila Dahmoush, Helen Y. Hougen
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Urology Case Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2214442025002360
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849233576921399296
author Victoria Gonzalez
Edward Linton
Timothy Boyce
Laila Dahmoush
Helen Y. Hougen
author_facet Victoria Gonzalez
Edward Linton
Timothy Boyce
Laila Dahmoush
Helen Y. Hougen
author_sort Victoria Gonzalez
collection DOAJ
description Small cell carcinoma of the bladder (SCCB) is a rare and aggressive variant of bladder cancer requiring multimodal treatment. We present a case of an 82-year-old male with SCCB with bulky pelvic adenopathy treated with a novel neoadjuvant combination of carboplatin, etoposide, and durvalumab with complete response of the small cell component. We also describe a rare complication of retinopathy resulting from this treatment. This study presents the potential efficacy and promise of adding immunotherapy to neoadjuvant chemotherapy for SCCB to achieve a long-term cure.
format Article
id doaj-art-d7769a5e42da48988a1acaa6560810a9
institution Kabale University
issn 2214-4420
language English
publishDate 2025-09-01
publisher Elsevier
record_format Article
series Urology Case Reports
spelling doaj-art-d7769a5e42da48988a1acaa6560810a92025-08-20T05:06:54ZengElsevierUrology Case Reports2214-44202025-09-016210316510.1016/j.eucr.2025.103165Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancerVictoria Gonzalez0Edward Linton1Timothy Boyce2Laila Dahmoush3Helen Y. Hougen4Department of Urology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA, 52242, USA; Corresponding author. 200 Hawkins Dr, Iowa City, IA, 52242, USA.Department of Ophthalmology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA, 52242, USADepartment of Ophthalmology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA, 52242, USADepartment of Pathology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA, 52242, USADepartment of Urology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA, 52242, USASmall cell carcinoma of the bladder (SCCB) is a rare and aggressive variant of bladder cancer requiring multimodal treatment. We present a case of an 82-year-old male with SCCB with bulky pelvic adenopathy treated with a novel neoadjuvant combination of carboplatin, etoposide, and durvalumab with complete response of the small cell component. We also describe a rare complication of retinopathy resulting from this treatment. This study presents the potential efficacy and promise of adding immunotherapy to neoadjuvant chemotherapy for SCCB to achieve a long-term cure.http://www.sciencedirect.com/science/article/pii/S2214442025002360Urinary bladder neoplasmsSmall cell carcinomaImmune checkpoint inhibitorRetinopathy
spellingShingle Victoria Gonzalez
Edward Linton
Timothy Boyce
Laila Dahmoush
Helen Y. Hougen
Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancer
Urology Case Reports
Urinary bladder neoplasms
Small cell carcinoma
Immune checkpoint inhibitor
Retinopathy
title Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancer
title_full Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancer
title_fullStr Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancer
title_full_unstemmed Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancer
title_short Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancer
title_sort novel use of carboplatin etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancer
topic Urinary bladder neoplasms
Small cell carcinoma
Immune checkpoint inhibitor
Retinopathy
url http://www.sciencedirect.com/science/article/pii/S2214442025002360
work_keys_str_mv AT victoriagonzalez noveluseofcarboplatinetoposideanddurvalumabasneoadjuvanttherapyintreatmentofsmallcellbladdercancer
AT edwardlinton noveluseofcarboplatinetoposideanddurvalumabasneoadjuvanttherapyintreatmentofsmallcellbladdercancer
AT timothyboyce noveluseofcarboplatinetoposideanddurvalumabasneoadjuvanttherapyintreatmentofsmallcellbladdercancer
AT lailadahmoush noveluseofcarboplatinetoposideanddurvalumabasneoadjuvanttherapyintreatmentofsmallcellbladdercancer
AT helenyhougen noveluseofcarboplatinetoposideanddurvalumabasneoadjuvanttherapyintreatmentofsmallcellbladdercancer